Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Looks To Add More Players To Digital Pre-Cert Pilot, And Launch Program

Executive Summary

The agency's associate director for digital health said the agency will expand its digital health pre-certification pilot program to get more input before the year's end. The agency hopes to launch an initial program based on the pilot by years end.

You may also be interested in...

Gottlieb Unveils Next Steps In Digital Health Plan

The US FDA Commissioner outlined six new updates to the agency's digital health plan, including a new guidance, the next steps for pre-certification and a digital health focus for drugs.

Gottlieb Defends US FDA 2019 Budget, Device Safety Plan In House

Members of a US House Appropriations Subcommittee interrogated FDA Commissioner Scott Gottlieb on the agency's proposed 2019 budget and his newly released device safety plan. One fierce critic, Rep. Rosa DeLauro, D-RI, attacked Gottlieb's efforts to allow third-party certifiers to approve device quality manufacturing processes, and said his safety plan looked like a "high-risk" action plan.

Gottlieb Wants To 'Bring Medtech Manufacturing Home' In 2019 Budget Request

US FDA would use a proposed $128m, 39% budget authority increase in 2019 Center for Devices funding over the prior year to promote domestic device manufacturing, and let low-risk digital health products receive streamlined approvals, among other budget priorities, says FDA Commissioner Scott Gottlieb.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts